Ba679BR Respimat

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ba679BR Respimat, covering 2013-10-29 to 2013-10-29. Get the full timeline:

Most recent: Clinical Trial Update: A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

See pricing